1
|
Yildiz SN, Entezari M, Paskeh MDA, Mirzaei S, Kalbasi A, Zabolian A, Hashemi F, Hushmandi K, Hashemi M, Raei M, Goharrizi MASB, Aref AR, Zarrabi A, Ren J, Orive G, Rabiee N, Ertas YN. Nanoliposomes as nonviral vectors in cancer gene therapy. MedComm (Beijing) 2024; 5:e583. [PMID: 38919334 PMCID: PMC11199024 DOI: 10.1002/mco2.583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 04/19/2024] [Accepted: 04/26/2024] [Indexed: 06/27/2024] Open
Abstract
Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off-targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions.
Collapse
Affiliation(s)
| | - Maliheh Entezari
- Department of GeneticsFaculty of Advanced Science and TechnologyTehran Medical SciencesIslamic Azad UniversityTehranIran
- Department of Medical Convergence SciencesFarhikhtegan Hospital Tehran Medical SciencesIslamic Azad UniversityTehranIran
| | - Mahshid Deldar Abad Paskeh
- Department of GeneticsFaculty of Advanced Science and TechnologyTehran Medical SciencesIslamic Azad UniversityTehranIran
- Department of Medical Convergence SciencesFarhikhtegan Hospital Tehran Medical SciencesIslamic Azad UniversityTehranIran
| | - Sepideh Mirzaei
- Department of BiologyFaculty of ScienceIslamic Azad UniversityScience and Research BranchTehranIran
| | - Alireza Kalbasi
- Department of PharmacyBrigham and Women's HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Amirhossein Zabolian
- Department of OrthopedicsShahid Beheshti University of Medical SciencesTehranIran
| | - Farid Hashemi
- Department of Comparative BiosciencesFaculty of Veterinary MedicineUniversity of TehranTehranIran
| | - Kiavash Hushmandi
- Department of Clinical Sciences InstituteNephrology and Urology Research CenterBaqiyatallah University of Medical SciencesTehranIran
| | - Mehrdad Hashemi
- Department of GeneticsFaculty of Advanced Science and TechnologyTehran Medical SciencesIslamic Azad UniversityTehranIran
- Department of Medical Convergence SciencesFarhikhtegan Hospital Tehran Medical SciencesIslamic Azad UniversityTehranIran
| | - Mehdi Raei
- Department of Epidemiology and BiostatisticsSchool of HealthBaqiyatallah University of Medical SciencesTehranIran
| | | | - Amir Reza Aref
- Belfer Center for Applied Cancer ScienceDana‐Farber Cancer InstituteHarvard Medical SchoolBostonMassachusettsUSA
- Department of Translational SciencesXsphera Biosciences Inc.BostonMassachusettsUSA
| | - Ali Zarrabi
- Department of Biomedical EngineeringFaculty of Engineering and Natural SciencesIstinye UniversityIstanbulTurkey
| | - Jun Ren
- Shanghai Institute of Cardiovascular DiseasesDepartment of CardiologyZhongshan HospitalFudan UniversityShanghaiChina
| | - Gorka Orive
- NanoBioCel Research GroupSchool of PharmacyUniversity of the Basque Country (UPV/EHU)Vitoria‐GasteizSpain
- University Institute for Regenerative Medicine and Oral Implantology ‐ UIRMI (UPV/EHU‐Fundación Eduardo Anitua)Vitoria‐GasteizSpain
- Bioaraba, NanoBioCel Research GroupVitoria‐GasteizSpain
- The AcademiaSingapore Eye Research InstituteSingaporeSingapore
| | - Navid Rabiee
- Centre for Molecular Medicine and Innovative TherapeuticsMurdoch UniversityPerthWestern AustraliaAustralia
| | - Yavuz Nuri Ertas
- Department of Biomedical EngineeringErciyes UniversityKayseriTurkey
- ERNAM—Nanotechnology Research and Application CenterErciyes UniversityKayseriTurkey
- UNAM−National Nanotechnology Research CenterBilkent UniversityAnkaraTurkey
| |
Collapse
|
2
|
Zhdanov VP. Release of molecules from nanocarriers. Phys Chem Chem Phys 2023; 25:28955-28964. [PMID: 37855700 DOI: 10.1039/d3cp01855e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2023]
Abstract
Release of drugs or vaccine molecules from macro-, micro-, and nano-sized carriers is usually considered to be limited by diffusion and/or carrier dissolution and/or erosion. The corresponding experimentally observed kinetics are customarily fitted by using the empirical Weibull and Korsemeyer-Peppas expressions. With decreasing size of carriers down to about 100 nm, the timescale of diffusion decreases, and accordingly the release can be kinetically limited, i.e., controlled by jumps of molecules located near the carrier-solution interface. In addition, nanocarriers (e.g., lipid nanoparticles) are often structurally heterogeneous so that the absorption of molecules there can be interpreted in terms of energetic heterogeneity, i.e., distribution of energies corresponding to binding sites and activation barriers for release. Herein, I present a general kinetic model aimed at such situations. For illustration, the deviation of the molecule binding energy from the maximum value was considered to be about 4-8 kcal mol-1. With this physically reasonable (for non-covalent interaction) scale of energetic heterogeneity, the predicted kinetics (i) are linear in the very beginning and then, with increasing time, become logarithmic and (ii) can be nearly perfectly fitted by employing the Weibull or Korsmeyer-Peppas expressions with the exponent in the range from 0.6 to 0.75. Such values of the exponent are often obtained in experiments and customarily associated with non-Fickian diffusion. My analysis shows that the energetic heterogeneity can be operative here as well.
Collapse
Affiliation(s)
- Vladimir P Zhdanov
- Section of Nano and Biophysics, Department of Physics, Chalmers University of Technology, Göteborg, Sweden.
- Boreskov Institute of Catalysis, Russian Academy of Sciences, Novosibirsk, Russia.
| |
Collapse
|
3
|
Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022; 7:166. [PMID: 35597779 PMCID: PMC9123296 DOI: 10.1038/s41392-022-01007-w] [Citation(s) in RCA: 169] [Impact Index Per Article: 84.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 04/04/2022] [Accepted: 04/19/2022] [Indexed: 02/06/2023] Open
Abstract
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide range of incurable diseases. Recent rapid advances in biotechnology and molecular medicine have enabled the production of almost any functional protein/peptide in the human body by introducing mRNA as a vaccine or therapeutic agent. This represents a rising precision medicine field with great promise for preventing and treating many intractable or genetic diseases. In addition, in vitro transcribed mRNA has achieved programmed production, which is more effective, faster in design and production, as well as more flexible and cost-effective than conventional approaches that may offer. Based on these extraordinary advantages, mRNA vaccines have the characteristics of the swiftest response to large-scale outbreaks of infectious diseases, such as the currently devastating pandemic COVID-19. It has always been the scientists’ desire to improve the stability, immunogenicity, translation efficiency, and delivery system to achieve efficient and safe delivery of mRNA. Excitingly, these scientific dreams have gradually been realized with the rapid, amazing achievements of molecular biology, RNA technology, vaccinology, and nanotechnology. In this review, we comprehensively describe mRNA-based therapeutics, including their principles, manufacture, application, effects, and shortcomings. We also highlight the importance of mRNA optimization and delivery systems in successful mRNA therapeutics and discuss the key challenges and opportunities in developing these tools into powerful and versatile tools to combat many genetic, infectious, cancer, and other refractory diseases.
Collapse
Affiliation(s)
- Shugang Qin
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Xiaoshan Tang
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yuting Chen
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Kepan Chen
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Na Fan
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Wen Xiao
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Qian Zheng
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Guohong Li
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yuqing Teng
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Min Wu
- Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, 58203, USA
| | - Xiangrong Song
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
| |
Collapse
|
4
|
Zhdanov VP. Lipid nanoparticles with ionizable lipids: Statistical aspects. Phys Rev E 2022; 105:044405. [PMID: 35590555 DOI: 10.1103/physreve.105.044405] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 04/04/2022] [Indexed: 06/15/2023]
Abstract
Lipid nanoparticles (LNPs) with size ∼100 nm are now used for fabrication of a new generation of drugs and antiviral vaccines. To optimize their function or, more specifically, interaction with cell membranes, their composition often includes ionizable lipids which are neutral or cationic (after association with H^{+}). Physically, such LNPs represent an interesting example of mesoscopic nanosystems with complex and far from understood properties. Experimentally, they can be studied at cell-membrane mimics. Herein, I analyze theoretically three related aspects. (i) I describe how the extent of protonation of ionizable lipids located at the surface of LNPs depends on the H^{+} concentration by using the phenomenological Langmuir-Stern and Poisson-Boltzmann models with continuum distribution of charges and the dipole model with discrete charges. In these frameworks, the H^{+} adsorption isotherms are predicted to be close to Langmuirian provided the fraction of ionizable lipids is smaller than 0.5. (ii) I scrutinize the interaction between charged LNPs and their interaction with a supported lipid bilayer (SLB) by using the phenomenological theory and lattice-gas model. The long-term association or attachment is predicted provided the charges are opposite. The models make it possible to estimate the size of the contact region (provided a LNP is not deformed) and the number of lipid-lipid bonds in this region. (iii) I briefly discuss denaturation of a LNP during interaction with the SLB and argue that it may occur via a few stepwise transitions.
Collapse
Affiliation(s)
- Vladimir P Zhdanov
- Section of Nano and Biophysics, Department of Physics, Chalmers University of Technology, Göteborg, Sweden and Boreskov Institute of Catalysis, Russian Academy of Sciences, Novosibirsk, Russia
| |
Collapse
|
5
|
Wu L, Zhou W, Lin L, Chen A, Feng J, Qu X, Zhang H, Yue J. Delivery of therapeutic oligonucleotides in nanoscale. Bioact Mater 2022; 7:292-323. [PMID: 34466734 PMCID: PMC8379367 DOI: 10.1016/j.bioactmat.2021.05.038] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 04/28/2021] [Accepted: 05/22/2021] [Indexed: 02/07/2023] Open
Abstract
Therapeutic oligonucleotides (TOs) represent one of the most promising drug candidates in the targeted cancer treatment due to their high specificity and capability of modulating cellular pathways that are not readily druggable. However, efficiently delivering of TOs to cancer cellular targets is still the biggest challenge in promoting their clinical translations. Emerging as a significant drug delivery vector, nanoparticles (NPs) can not only protect TOs from nuclease degradation and enhance their tumor accumulation, but also can improve the cell uptake efficiency of TOs as well as the following endosomal escape to increase the therapeutic index. Furthermore, targeted and on-demand drug release of TOs can also be approached to minimize the risk of toxicity towards normal tissues using stimuli-responsive NPs. In the past decades, remarkable progresses have been made on the TOs delivery based on various NPs with specific purposes. In this review, we will first give a brief introduction on the basis of TOs as well as the action mechanisms of several typical TOs, and then describe the obstacles that prevent the clinical translation of TOs, followed by a comprehensive overview of the recent progresses on TOs delivery based on several various types of nanocarriers containing lipid-based nanoparticles, polymeric nanoparticles, gold nanoparticles, porous nanoparticles, DNA/RNA nanoassembly, extracellular vesicles, and imaging-guided drug delivery nanoparticles.
Collapse
Affiliation(s)
- Lei Wu
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, 510006, Guangdong, China
| | - Wenhui Zhou
- Pharmaceutical Sciences Laboratory and Turku Bioscience Centre, Åbo Akademi University, Turku, 20520, Finland
- Southern Medical University Affiliated Fengxian Hospital, Shanghai, 201499, China
| | - Lihua Lin
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, 510006, Guangdong, China
| | - Anhong Chen
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, 510006, Guangdong, China
| | - Jing Feng
- Southern Medical University Affiliated Fengxian Hospital, Shanghai, 201499, China
| | - Xiangmeng Qu
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, 510006, Guangdong, China
| | - Hongbo Zhang
- Pharmaceutical Sciences Laboratory and Turku Bioscience Centre, Åbo Akademi University, Turku, 20520, Finland
| | - Jun Yue
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, 510006, Guangdong, China
| |
Collapse
|
6
|
Zhang X, Guan G, Wang Z, Lv L, Chávez-Madero C, Chen M, Yan Z, Yan S, Wang L, Li Q. Drug release evaluation of Paclitaxel/Poly-L-Lactic acid nanoparticles based on a microfluidic chip. Biomed Microdevices 2021; 23:57. [PMID: 34762163 DOI: 10.1007/s10544-021-00596-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/28/2021] [Indexed: 12/22/2022]
Abstract
Paclitaxel is a commonly used drug in the medical field because of its strong anticancer effect. However, it may produce relatively severe side effects (i.e., allergic reactions). A major characteristic of paclitaxel is low solubility in water. Special solvents are used for dissolving paclitaxel and preparing the paclitaxel drugs, while the solvents themselves will cause certain effects. Polyoxyethylene castor oil, for example, can cause severe allergic reactions in some people, and the clinical use is limited. In this study, we developed a new Paclitaxel/Poly-L-Lactic Acid (PLLA) nanoparticle drug, which is greatly soluble in water, and carried out in vitro drug sustained release research on it and the original paclitaxel drug. However, because the traditional polymer drug carrier usually uses dialysis bag and thermostatic oscillation system to measure the drug release degree in vitro, the results obtained are greatly different from the actual drug release results in human body. Therefore, this paper adopts the microfluidic chip we previously developed to mimic the human blood vessels microenvironment to study the sustained-release of Paclitaxel/PLLA nanoparticles to make the results closer to the release value in human body. The experimental results showed that compared with the original paclitaxel drug, Paclitaxel/PLLA nanoparticles have a long-sustained release time and a slow drug release, realizing the sustained low-dose release of paclitaxel, a cell cycle-specific anticancer drug, and provided certain reference significance and theoretical basis for the research and development of anticancer drugs.
Collapse
Affiliation(s)
- Xiang Zhang
- School of Mechanics & Safety Engineering, Zhengzhou University, Zhengzhou, 450001, China. .,Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA. .,National Center for International Joint Research of Micro-Nano Molding Technology, Zhengzhou University, Zhengzhou, 450001, China. .,Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, 450001, China.
| | - Guotao Guan
- School of Mechanics & Safety Engineering, Zhengzhou University, Zhengzhou, 450001, China.,National Center for International Joint Research of Micro-Nano Molding Technology, Zhengzhou University, Zhengzhou, 450001, China.,Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, 450001, China
| | - Zhenxing Wang
- School of Mechanics & Safety Engineering, Zhengzhou University, Zhengzhou, 450001, China.,National Center for International Joint Research of Micro-Nano Molding Technology, Zhengzhou University, Zhengzhou, 450001, China.,Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, 450001, China
| | - Li Lv
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA.,Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China
| | - Carolina Chávez-Madero
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA.,Departamento de Ingeniería Mecatrónica Y Electrónica, Escuela de Ingeniería Y Ciencias, Tecnologico de Monterrey, Monterrey, 64849, NL, México
| | - Mo Chen
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA.,Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China
| | - Zhenhao Yan
- School of Mechanics & Safety Engineering, Zhengzhou University, Zhengzhou, 450001, China.,National Center for International Joint Research of Micro-Nano Molding Technology, Zhengzhou University, Zhengzhou, 450001, China.,Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, 450001, China
| | - Shujie Yan
- School of Mechanics & Safety Engineering, Zhengzhou University, Zhengzhou, 450001, China.,National Center for International Joint Research of Micro-Nano Molding Technology, Zhengzhou University, Zhengzhou, 450001, China.,Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, 450001, China
| | - Lixia Wang
- School of Mechanics & Safety Engineering, Zhengzhou University, Zhengzhou, 450001, China.,National Center for International Joint Research of Micro-Nano Molding Technology, Zhengzhou University, Zhengzhou, 450001, China.,Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, 450001, China
| | - Qian Li
- School of Mechanics & Safety Engineering, Zhengzhou University, Zhengzhou, 450001, China. .,National Center for International Joint Research of Micro-Nano Molding Technology, Zhengzhou University, Zhengzhou, 450001, China. .,Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, 450001, China.
| |
Collapse
|
7
|
Zhdanov VP. How nanoparticles can induce dimerization and aggregation of cells in blood or lymph. Biosystems 2021; 210:104551. [PMID: 34597710 DOI: 10.1016/j.biosystems.2021.104551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 09/19/2021] [Accepted: 09/21/2021] [Indexed: 12/24/2022]
Abstract
By analogy with virions, the binding of biologically-inspired nanoparticles (NPs) with ligands to the cellular membrane containing receptors depends on the multivalent ligand-receptor interaction, membrane bending, and cytoskeleton deformation. The interplay of these factors results in the existence of the potential minimum and activation barrier on the pathway towards full absorption of a NP. Herein, I hypothesize and show theoretically that the interaction of a NP, bound to one cell, with another cell can stabilize the potential minimum and increase the corresponding activation barrier, i.e., NPs can mediate the formation of long-living pairs of cells and aggregates containing a few cells inside blood and lymphatic vessels.
Collapse
Affiliation(s)
- Vladimir P Zhdanov
- Section of Nano and Biophysics, Department of Physics, Chalmers University of Technology, Göteborg, Sweden; Boreskov Institute of Catalysis, Russian Academy of Sciences, Novosibirsk, Russia.
| |
Collapse
|
8
|
Zhdanov VP. Virology from the perspective of theoretical colloid and interface science. Curr Opin Colloid Interface Sci 2021; 53:101450. [PMID: 36568530 PMCID: PMC9761319 DOI: 10.1016/j.cocis.2021.101450] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Viral infections occur at very different length and time scales and include various processes, which can often be described using the models developed and/or employed in colloid and interface science. Bearing in mind the currently active COVID-19, I discuss herein the models aimed at viral transmission via respiratory droplets and the contact of virions with the epithelium. In a more general context, I outline the models focused on penetration of virions via the cellular membrane, initial stage of viral genome replication, and formation of viral capsids in cells. In addition, the models related to a new generation of drug delivery vehicles, for example, lipid nanoparticles with size about 100-200 nm, are discussed as well. Despite the high current interest in all these processes, their understanding is still limited, and this area is open for new theoretical studies.
Collapse
Affiliation(s)
- Vladimir P Zhdanov
- Section of Nano and Biological Physics, Department of Physics, Chalmers University of Technology, Göteborg, Sweden
- Boreskov Institute of Catalysis, Russian Academy of Sciences, Novosibirsk, Russia
| |
Collapse
|
9
|
Zhdanov VP. Ligand-receptor-mediated attachment of lipid vesicles to a supported lipid bilayer. EUROPEAN BIOPHYSICS JOURNAL : EBJ 2020; 49:395-400. [PMID: 32556429 PMCID: PMC7351846 DOI: 10.1007/s00249-020-01441-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/16/2020] [Revised: 04/26/2020] [Accepted: 06/01/2020] [Indexed: 12/31/2022]
Abstract
The interaction of exosomes (cell-secreted [Formula: see text]100 nm-sized extracellular vesicles) or membrane-enveloped virions with cellular lipid membranes is often mediated by relatively weak ligand-receptor bonds. Interactions of this type can be studied using vesicles and observing their attachment to receptors located in a lipid bilayer formed at a solid surface. The contact region between a vesicle and the supported lipid bilayer and accordingly the number of ligand-receptor pairs there can be increased by deforming a vesicle. Herein, I (i) estimate theoretically the corresponding deformation energy assuming a disk-like or elongated shape of vesicles, (ii) present the equations allowing one to track such deformations by employing total internal reflection fluorescence microscopy and surface plasmon resonance, and (iii) briefly discuss some related experimental studies.
Collapse
Affiliation(s)
- Vladimir P Zhdanov
- Section of Biological Physics, Department of Physics, Chalmers University of Technology, Göteborg, Sweden.
- Boreskov Institute of Catalysis, Russian Academy of Sciences, Novosibirsk, Russia.
| |
Collapse
|
10
|
Yan H, Hu Y, Akk A, Rai MF, Pan H, Wickline SA, Pham CT. Induction of WNT16 via Peptide-mRNA Nanoparticle-Based Delivery Maintains Cartilage Homeostasis. Pharmaceutics 2020; 12:pharmaceutics12010073. [PMID: 31963412 PMCID: PMC7022671 DOI: 10.3390/pharmaceutics12010073] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Revised: 12/27/2019] [Accepted: 01/13/2020] [Indexed: 01/02/2023] Open
Abstract
Osteoarthritis (OA) is a progressive joint disease that causes significant disability and pain and for which there are limited treatment options. We posit that delivery of anabolic factors that protect and maintain cartilage homeostasis will halt or retard OA progression. We employ a peptide-based nanoplatform to deliver Wingless and the name Int-1 (WNT) 16 messenger RNA (mRNA) to human cartilage explants. The peptide forms a self-assembled nanocomplex of approximately 65 nm in size when incubated with WNT16 mRNA. The complex is further stabilized with hyaluronic acid (HA) for enhanced cellular uptake. Delivery of peptide-WNT16 mRNA nanocomplex to human cartilage explants antagonizes canonical β-catenin/WNT3a signaling, leading to increased lubricin production and decreased chondrocyte apoptosis. This is a proof-of-concept study showing that mRNA can be efficiently delivered to articular cartilage, an avascular tissue that is poorly accessible even when drugs are intra-articularly (IA) administered. The ability to accommodate a wide range of oligonucleotides suggests that this platform may find use in a broad range of clinical applications.
Collapse
Affiliation(s)
- Huimin Yan
- Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; (H.Y.); (Y.H.)
- John Cochran Veterans Affairs Medical Center, St. Louis, MO 63106, USA
| | - Ying Hu
- Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; (H.Y.); (Y.H.)
- John Cochran Veterans Affairs Medical Center, St. Louis, MO 63106, USA
| | - Antonina Akk
- Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; (H.Y.); (Y.H.)
| | - Muhammad Farooq Rai
- Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA;
| | - Hua Pan
- Department of Cardiovascular Sciences, University of South Florida, Tampa, FL 33620, USA;
| | - Samuel A. Wickline
- Department of Cardiovascular Sciences, University of South Florida, Tampa, FL 33620, USA;
- Correspondence: (S.A.W.); (C.T.N.P.)
| | - Christine T.N. Pham
- Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; (H.Y.); (Y.H.)
- John Cochran Veterans Affairs Medical Center, St. Louis, MO 63106, USA
- Correspondence: (S.A.W.); (C.T.N.P.)
| |
Collapse
|